Diseases & Conditions
Grants & Contracts
News & Events
NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.
In vivo imaging is gaining increasing interest for the characterization of infectious diseases, including the ones caused by high-consequence pathogens.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
The pathology department and histology laboratory at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) work together to develop and use established animal models of high-consequence emerging human viruses to study disease pathogenesis and facilitate countermeasure development under
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Chemical Countermeasures Research Program (CCRP) supports the discovery and early development of medical countermeasures (MCMs) to treat the acute and/or long-term chronic toxicities after exposure to highly tox
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
The virology team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has extensive expertise working with a range of high‑consequence viral pathogens.